Washington, D.C. (April 12, 2016) The Biotechnology Innovation Organization (BIO) is pleased to announce that it will be holding an Intellectual Property Symposium as part of BIO’s 13th Annual World Congress on Industrial Biotechnology. The IP Symposium: “Where IP meets IB” will take place on April 20, 2016 and consist of two panels of experts who will highlight the value of intellectual property in industrial biotechnology. The world’s largest industrial biotechnology event will be held April 17-20, 2016 at the San Diego Convention Center in San Diego, CA.
“Intellectual Property is critical to protecting innovation and attracting investment for industrial biotech companies. Understanding how to properly protect innovation is highly important to the future success of this industry,” said Brent Erickson, executive vice president for BIO’s Industrial & Environmental Section. “BIO is pleased to be able to provide attendees at this year’s World Congress on Industrial Biotechnology a unique view into the important role that patents play in this sector.”
On Wednesday, April 20, 2016 from 8:30am – 10:00am, Robins and Kaplan, LLP will sponsor the “Assessing and Preserving Value in Biotechnology Intellectual Property” session. Here, panelists will provide guidance on maintaining IP value while conducting the business of using and commercializing technologies.
The panel will be moderated by Matthew McFarlane, Robins Kaplan LLP, and include:
- Reena R. Desai, Synthetic Genomics, Inc.
- David Dodds, Dodds & Associates
- Sherry Roberg-Perez, Robins Kaplan LLP
The “Procuring Patents for Industrial Biotechnology Innovations” will follow the first IP session and is scheduled from 10:30am – 12:00pm. Sponsored by Finnegan, panelists will focus on the special challenges in securing patents in the industrial biotechnology area, primarily using 3D bioprinting and biofabrication innovations as representative examples. Experts will also provide an overview of emerging trends in industrial biotechnology innovations including the 3D bioprinting and biofabrication innovations of the panelists, and then turn to the threshold question of patent eligibility for such innovations under the current interpretations and applications of 35 USC 101.
Moderated by Barbara Rudolph, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, panelists include:
- Hans Sauer, Biotechnology Innovation Organization
- Len Smith, Heliae
- Kai Rajan, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
All programs at the World Congress on Industrial Biotechnology are open to attendance by members of the media. Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.
For more information on the conference, please visit http://go.bio.org/WorldCongress2016.html. For assistance, please contact worldcongress@bio.org.
About BIO
BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.